Endocrinology Research and Practice
Original Articles

Growth Differentiation Factor 15 in Patients with Acromegaly: A Case–Control Study


Department of Endocrinology and Metabolism, Çanakkale Mehmet Akif Ersoy State Hospital, Çanakkale, Türkiye


Department of Endocrinology and Metabolism, Ankara Etlik City Hospital, Ankara, Türkiye


Department of Endocrinology and Metabolism, Defa Life Hospital, Gaziantep, Türkiye


Department of Endocrinology and Metabolism, Iğdır Dr. Nevruz Erez State Hospital, Iğdır, Türkiye

Endocrinol Res Pract 2024; 28: 138-142
DOI: 10.5152/erp.2024.24424
Read: 113 Downloads: 75 Published: 30 May 2024

Objective: It was previously shown that the levels of several biomarkers increase due to acromegaly disease-related inflammation, and some markers are parallel to the disease’s activity. The current study compared the possible relationship of growth differentiation factor-15 (GDF-15) with acromegaly disease activity in healthy subjects.

Methods: This case–control study was conducted in a single center. It included 40 acromegaly patients (25 active/15 controlled) (47.7 ± 9.4 years, 20 female/20 male) and 24 healthy individuals (49.9 ± 10.1 years, 13 female/11 male) with age–sex–body mass index similar to the patient group. Demographic data, metabolic and hormonal parameters, and GDF-15 levels of the study population were studied.

Results: The median GDF-15 levels were significantly higher in patients with acromegaly compared to healthy subjects (HS) (280.4 (Q1-Q3: 197.0-553.2) vs. 213.3 (Q1-Q3: 179.9-297.2) ng/L, P =  .01). Serum GDF-15 levels of active and controlled acromegaly patients were comparable (P = .39). Interestingly, compared to HS, GDF-15 levels were significantly higher in controlled disease (P = .013), whereas GDF-15 levels tended to be higher in active disease but did not reach statistical significance (P = .06). Growth differentiation factor-15 levels were positively correlated with fasting plasma glucose (r = 0.304, P = .01) and HbA1c (r = 0.292, P = .02). When evaluated across the entire cohort, GDF15 levels were found to be higher in diabetic patients compared to non-diabetic individuals (P = .04).

Conclusion: Plasma GDF-15 levels were increased in the patients with acromegaly compared to healthy subjects. This increment may be due to accompanying diseases such as diabetes rather than a disease-specific effect.

Cite this article as: Bostan H, Hepşen S, Gül Ü, et al. Growth differentiation factor 15 in patients with acromegaly: A case–control study. Endocrinol Res Pract. 2024;28(3):138- 142.

EISSN 2822-6135